Add bacteriostatic (BAC) water slowly down the inside wall of your vial containing lyophilized (freeze-dried) peptide. Swirl gently to dissolve. Never shake, as agitation can denature the peptide. The volume of BAC water you add sets the concentration (mg/mL), which sets how many syringe units equal your target dose. Store reconstituted peptides refrigerated at 2-8°C (36-46°F) and use within 4-6 weeks.

It depends on your vial size and desired dose. Less water = higher concentration (fewer units per dose). More water = lower concentration (more units, easier to measure on the syringe). The sweet spot is a draw between 10-50 units, where insulin syringes are most precise. For a 5mg vial with a 0.25mg dose, 1-2 mL of BAC water typically produces a convenient 10-20 unit draw.

BAC water is sterile water containing 0.9% benzyl alcohol, which inhibits bacterial growth. It keeps reconstituted peptides stable for 4-6 weeks when refrigerated. Plain sterile water should be discarded within 24 hours. Always use BAC water (not saline or plain sterile water) because the preservative prevents contamination from repeated needle punctures into the same vial.

A COA is an independent lab report showing the actual tested amount of peptide in your vial, which often differs from the label. A vial labeled "10 mg" may contain 9.2 mg or 10.8 mg. Using the COA-verified amount instead of the label amount ensures your dosing math is accurate. Always request a COA from your supplier and enter that amount in DrawDose.

On a U-100 insulin syringe, 100 units = 1 mL = 1 cc. To find your draw: divide vial amount (mg) by BAC water volume (mL) to get concentration. Then divide your dose by that concentration to get volume in mL. Multiply by 100 for syringe units. Example: 10mg vial + 2mL BAC water = 5 mg/mL. For a 0.25mg dose: 0.25 ÷ 5 = 0.05 mL = 5 units.

Peptide injections use U-100 insulin syringes in three sizes: 0.3 mL (30 units), 0.5 mL (50 units), or 1 mL (100 units). Smaller syringes are more precise for small doses. Pick the smallest syringe that fits your calculated draw volume. FDA: Needles and Syringes

Most peptides are injected subcutaneously (SubQ) into fat tissue: abdomen (at least 2 inches from navel), outer thigh, or back of the upper arm, at a 45-90° angle. Intramuscular (IM) injections go into muscle: deltoid (up to 2 mL), vastus lateralis (outer thigh), or ventrogluteal (hip) at 90°. Ask your healthcare provider which method fits your compound.

Injecting the same spot repeatedly causes lipohypertrophy (fat buildup) or lipoatrophy (fat loss), which leads to scar tissue and erratic absorption. Nearly half of insulin users develop lipohypertrophy from poor rotation. A practical method: divide each injection area into four quadrants, use one quadrant per week moving clockwise, keep each injection at least 1 inch (2.5 cm) from the last, and wait 7-14 days before returning to the same spot.

Semaglutide is a GLP-1 receptor agonist prescribed for weight management and blood sugar control. Typical titration: 0.25 mg once weekly for 4 weeks, then 0.5 mg, 1 mg, and up to 2.4 mg based on tolerance. Injected SubQ, usually in the abdomen or thigh.

Tirzepatide targets both GIP and GLP-1 receptors. The titration starts at 2.5 mg weekly for 4 weeks, then steps up through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg. Injected SubQ. Each titration step changes the syringe draw, so recalculating after each increase matters.

Retatrutide targets three receptors at once: GIP, GLP-1, and glucagon. Still in clinical trials, Phase 2 data showed up to 24% body weight reduction over 48 weeks. Injected SubQ with a titration protocol starting at lower doses.

Body Protection Compound-157 is a 15-amino-acid peptide studied for tissue repair. Research doses are typically 200-500 mcg per day, injected SubQ near the area of concern. Also available as BPC-157 Arginate (the arginine salt form). Often paired with TB-500 in blend protocols.

TB-500 plays a role in cell migration and tissue repair. Research dosing is usually 2-5 mg twice weekly during a loading phase, dropping to 2-5 mg every 1-2 weeks for maintenance. Frequently combined with BPC-157 in a single blend vial.

This is one of the most common growth hormone secretagogue stacks. CJC-1295 (with or without DAC) stimulates GHRH, and Ipamorelin is a selective ghrelin receptor agonist. Research doses: 100-300 mcg each, often combined in a single injection before bed. Available with or without DAC (Drug Affinity Complex), which extends the half-life.

Beyond the compounds above, DrawDose covers 70+ peptides: GLP-1 compounds (Liraglutide, Survodutide, AOD-9604), healing peptides (KPV, LL-37, Larazotide), GH secretagogues (GHRP-2, GHRP-6, Tesamorelin, Sermorelin, Hexarelin), cognitive peptides (Selank, Semax, Dihexa), and anti-aging compounds (Epitalon, GHK-Cu, MOTS-c, NAD+). Each has pre-filled starting doses and protocol references.